Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Other factors that may contribute to nausea during retatrutide treatment include: Central nervous system effects : GLP-1 receptors are present in brain regions involved in nausea and vomiting, including the area postrema, and activation of these pathways is thought to contribute to the emetogenic effects of this drug class [15] [16] Dose escalation : Rapid increases in dose are more likely to provoke symptoms than gradual titration Individual variability : Genetic, metabolic, and lifestyle factors can influence how sensitive a person is to these effects Dietary habits : Eating large, fatty, or rich meals may worsen nausea in those taking GLP-1-based therapies These mechanisms are not unique to retatrutide and are shared to varying degrees across the entire class of incretin-based medicines
Enforcement discretion reflects agency priorities
doi: 10.1056/NEJMoa1612917 8 HernandezAFGreenJBJanmohamedSDAgostinoRB SrGrangerCBJonesNPet al
Function over mass : Earlier anti-myostatin antibodies (domagrozumab, stamulumab) increased muscle mass but failed to improve function
